NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00284258,Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer,https://clinicaltrials.gov/study/NCT00284258,,COMPLETED,"This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with FOLFIRI.",NO,Colorectal Cancer,"DRUG: CPT-11 and TS-1|DRUG: CPT-11, 5-FU and l-LV","Progression free survival, every course for first three courses, then every other course","Over all survival, Response rate, Adverse event, Medical economy, adverse events will be collected during treatment",,"Taiho Pharmaceutical Co., Ltd.","Daiichi Sankyo Co., Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,426,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,01023010 / TOP-003,2006-01,2010-07,2010-08,2006-01-31,,2012-11-02,"Saku Central Hospital, Saku City, Nagano, 384-0301, Japan",
